Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

714 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Statin treatment and stroke outcome in the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial.
Goldstein LB, Amarenco P, Zivin J, Messig M, Altafullah I, Callahan A, Hennerici M, MacLeod MJ, Sillesen H, Zweifler R, Michael K, Welch A; Stroke Prevention by Aggressive Reduction in Cholesterol Levels Investigators. Goldstein LB, et al. Among authors: hennerici m. Stroke. 2009 Nov;40(11):3526-31. doi: 10.1161/STROKEAHA.109.557330. Epub 2009 Sep 10. Stroke. 2009. PMID: 19745172 Clinical Trial.
Effects of intense low-density lipoprotein cholesterol reduction in patients with stroke or transient ischemic attack: the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial.
Amarenco P, Goldstein LB, Szarek M, Sillesen H, Rudolph AE, Callahan A 3rd, Hennerici M, Simunovic L, Zivin JA, Welch KM; SPARCL Investigators. Amarenco P, et al. Among authors: hennerici m. Stroke. 2007 Dec;38(12):3198-204. doi: 10.1161/STROKEAHA.107.493106. Epub 2007 Oct 25. Stroke. 2007. PMID: 17962589 Clinical Trial.
Relative effects of statin therapy on stroke and cardiovascular events in men and women: secondary analysis of the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Study.
Goldstein LB, Amarenco P, Lamonte M, Gilbert S, Messig M, Callahan A, Hennerici M, Sillesen H, Welch KM; SPARCL Investigators. Goldstein LB, et al. Among authors: hennerici m. Stroke. 2008 Sep;39(9):2444-8. doi: 10.1161/STROKEAHA.107.513747. Epub 2008 Jul 10. Stroke. 2008. PMID: 18617654 Clinical Trial.
Risk of stroke and cardiovascular events after ischemic stroke or transient ischemic attack in patients with type 2 diabetes or metabolic syndrome: secondary analysis of the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial.
Callahan A, Amarenco P, Goldstein LB, Sillesen H, Messig M, Samsa GP, Altafullah I, Ledbetter LY, MacLeod MJ, Scott R, Hennerici M, Zivin JA, Welch KM; SPARCL Investigators. Callahan A, et al. Among authors: hennerici m. Arch Neurol. 2011 Oct;68(10):1245-51. doi: 10.1001/archneurol.2011.146. Epub 2011 Jun 13. Arch Neurol. 2011. PMID: 21670382 Clinical Trial.
High-dose atorvastatin after stroke or transient ischemic attack.
Amarenco P, Bogousslavsky J, Callahan A 3rd, Goldstein LB, Hennerici M, Rudolph AE, Sillesen H, Simunovic L, Szarek M, Welch KM, Zivin JA; Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Investigators. Amarenco P, et al. Among authors: hennerici m. N Engl J Med. 2006 Aug 10;355(6):549-59. doi: 10.1056/NEJMoa061894. N Engl J Med. 2006. PMID: 16899775 Free article. Clinical Trial.
Transient ischemic attacks are more than "ministrokes".
Daffertshofer M, Mielke O, Pullwitt A, Felsenstein M, Hennerici M. Daffertshofer M, et al. Among authors: hennerici m. Stroke. 2004 Nov;35(11):2453-8. doi: 10.1161/01.STR.0000144050.90132.8e. Epub 2004 Oct 14. Stroke. 2004. PMID: 15486333
714 results